JULIA DERENZI: Open Payments
NPI 1932369469 · SAN RAMON, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,529 in 68 payments from 13 companies in 2025. Trend: 2023 $2,087 · 2024 $1,893 · 2025 $1,529
Food & beverage: $1,529
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 29 | $668 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $152 |
| Madrigal Pharmaceuticals | 5 | $113 |
| Aimmune Therapeutics, Inc. | 4 | $99 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $95 |
| Janssen Biotech, Inc. | 4 | $93 |
| Lilly USA, LLC | 3 | $71 |
| Ardelyx, Inc. | 3 | $69 |
| Ipsen Biopharmaceuticals, Inc | 3 | $52 |
| Braintree Laboratories, Inc. | 1 | $33 |
Products named: CREON, RINVOQ, ENTYVIO, REZDIFFRA, ZENPEP, XIFAXAN, TREMFYA, OMVOH.
Industry payments across CA — which companies pay providers there.
